Berdagang Vir Biotechnology VIR

Jual
 Beli

VirBiotechnology carta live

5m 15m 30m 1h 4h 1d 1w

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tunjukkan lebih lagi
Ava Grace 2025 Aug 06, 15:20

Trump Imposes Tariffs on India Over Russian Energy Imports Amid Ukraine Tensions

Liam James 2025 Aug 06, 14:20

Kashkari Hints at Possible Near-Term Rate Cut Amidst Economic Slowdown

Emma Rose 2025 Aug 06, 13:20

Global Stock Markets Defy Recession Fears: AI and Liquidity Fuel Rally

Ava Grace 2025 Aug 06, 11:20

Trump's Tariffs on Russian Oil: Potential Impact on US and Global Economy

Noah Lee 2025 Aug 06, 10:20

Berkshire Hathaway's Underperformance: Succession Concerns and Market Shifts

Sophia Claire 2025 Aug 06, 09:20

White House Races Against Deadline to Resolve Russia-Ukraine Conflict

Noah Lee 2025 Aug 06, 03:20

Trump Admin Mulls Sanctions on Russian 'Shadow Fleet' If Moscow Doesn't Agree to Ceasefire

Emma Rose 2025 Aug 06, 01:20

Trump's Fed Chair Comments Spark Speculation: A Market Analysis

Maklumat

Sebaran nilai

0.05

Spread (%)

0.9940 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran ditutup

Khamis

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Jumaat

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

706396224

Saham Tertunggak

138238000

Tarikh Pendapatan (Seterusnya)

0000-00-00

Hasil Div

Tarikh Selepas Dividen

Kadar dividen tahunan depan

0

Hasil dividen tahunan depan

0

EPS

-4.23

Ketahui lebih lanjut mengenai instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumen Berkaitan

Aset
Jual
Beli
Perubahan (%):

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang
Instrumen Berkaitan

latest_education_articles

Tunjukkan lebih lagi
Trustpilot